Progress with diabetic patients undergoing percutaneous coronary intervention

European Heart Journal

Volumn 25, Issue 2, 2004, Pages 99-100

  Cohen, Marc ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; RAPAMYCIN;

CORONARY STENT; DIABETES MELLITUS; EDITORIAL; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; DIABETIC ANGIOPATHIES; HUMANS;

EID: 1642471652     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.11.001     Document Type: Editorial

References (5)

1. Detre KM, Guo P, Holubkov R et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;91:633-40.
2. Abizaid A, Costa MA, Albertal M et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: Insights from the RAVEL trial. Eur Heart J 2004;25:107-12.
3. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
4. Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
5. Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT diabetic study. Circulation 1999;100:2477-84.